Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2023-07-07 00:00:00 ET · period of report 2023-07-07 · accession 0001209191-23-041866 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-07-07 | 2023-07-07 | SPRY | Shawver Laura | Dir | S - Sale+OE | $6.36 | -8,858 | 210.3K | -4% | -$56.3K |
| D | 2023-07-07 | 2023-07-07 | SPRY | Shawver Laura | Dir | M - OptEx | $1.27 | +8,858 | 219.2K | +4% | +$11.2K |
| D | 2023-07-07 | 2023-07-07 | SPRY | Shawver Laura | Dir | M - OptEx | $0.00 | -8,858 | 103.0K | -8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-07 | S | D | 8,858 | $6.36 | 210,346 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $6.21 to $6.56, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. |
| 2 | Common | Common Stock | 2023-07-07 | M | A | 8,858 | $1.27 | 219,204 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-07-07 | M | D | 8,858 | $0.00 | 102,997 | D | $1.27 · — to 2030-04-28 | 8,858 Common Stock | (F3) Immediately exercisable. |